Changes in weight and lean body mass during highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 39, Issue 8, 2004, Pages 1223-1230

  Shikuma, C M ^a,g   Zackin, R ^b   Sattler, F ^c   Mildvan, D ^e   Nyangweso, P ^b   Alston, B ^f   Evans, S ^b   Mulligan, K ^d  

^a UNIVERSITY OF HAWAII   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; LEAN BODY WEIGHT; LYMPHOCYTE COUNT; MALE; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RNA VIRUS; T LYMPHOCYTE; VIRUS LOAD;

ADIPOSITY; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; WEIGHT GAIN;

EID: 12844273480     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424665     Document Type: Article

References (29)

1. Ott M, Lembcke B, Fischer H, et al. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr 1993; 57:15-9.
2. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:411-8.
3. Batterham MJ, Garsia R, Greenop P. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy. Int J STD AIDS 2002; 13:744-7.
4. Teixeira A, Leu JC, Honderlick P, Trylesinski A, Zucman D. Variation in body weight and plasma viral load in HIV patients treated with tritherapy including a protease inhibitor. Nutrition 1997; 13:269.
5. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-related wasting. AIDS 1998; 12:1777-84.
6. Pernerstorfer-Schoen H, Schindler K, Parschalk B, et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a cpmparison between HIV-infected and AIDS patients. AIDS 1999; 13:2389-96.
7. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir. AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182:1375-84.
8. Hammer SM, Bassett R, Squires KE, et al. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antiviral Ther 2003; 8:507-18.
9. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen: ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
10. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-34.
11. Hammer SM, Vaida F, Bennett KK, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-80.
12. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303.
13. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996; 64:489S-97S.
14. O'Dell MW, Lubeck DP, O'Driscoll P, Matsuno S. Validity of the Karnofsky performance status in an HIV-infected sample. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:350-7.
15. Daughton DM, Fix AJ, Kass I, Bell CW, Patil KD. Maximum oxygen consumption and the ADAPT quality-of-life scale. Arch Phys Med Rehabil 1982; 63:620-2.
16. Johansen KL, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr 2003; 77:842-6.
17. Teixeira-Salmela LF, Olney SJ, Nadeau S, Brouwer B. Muscle strengthening and physical conditioning to reduce impairment and disability in chronic stroke survivors. Arch Phys Med Rehabil 1999; 80:1211-8.
18. Farrell MJ, Gibson SJ, Helme RD. Measuring the activity of older people with chronic pain. Clin J Pain 1996; 12:6-12.
19. Fix AJ, Daughton DM. Human activity profile professional manual. Odessa, FL: PAR Psychological Assessment Resources, 1988.
20. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282:2305-12.
21. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002; 3:229-38.
22. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12:1645-51.
23. Schwenk A, Kremer G, Cornely O, Diehl V, Fatkenheuer G, Salzberger B. Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Nutrition 1999; 15:453-7.
24. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 2002; 31:230-6.
25. Smit E, Skolasky RL, Dobs AS, et al. Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol 2002; 156:211-8.
26. Roubenoff R, Grinspoon S, Skolnik PR, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 2002; 283:E138-45.
27. Ellis KJ, Bell SJ, Chertow GM, et al. Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference. Nutrition 1999; 15:874-80.
28. Corcoran C, Anderson EJ, Burrows B, et al. Comparison of total body potassium with other techniques for measuring lean body mass in men and women with AIDS wasting. Am J Clin Nutr 2000; 72:1053-8.
29. Grinspoon S, Corcoran C, Rosenthal D, et al. Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab 1999; 84:201-6.